Trial Profile
Prospective, randomized, open-label, clinical trial evaluating the effects of vildagliptin on progression of atherosclerotic plaques in type 2 diabetic patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 24 May 2018 Status changed from recruiting to discontinued.
- 16 Sep 2013 New trial record